ings, the pathologic findings and the management of this type of lesion. Surgeons should be aware that myoid hamartoma is a rare benign tumor, but it can be the cause of a palpable mass in the breast.
INTRODUCTION
Breast parenchymal hamartomas comprise approximately 0.7% of all benign tumors of the female breast. (1) Arrigoni et al. (2) in 1971, first described mammary hamartomas as lesions composed of a haphazard overgrowth of mature tissues. Myoid hamartoma is a rare subtype of hamartomas that is characterized by the presence of smooth muscle cells. Only 15 cases of myoid hamartoma have been reported in the English medical literature. (3) and 2 cases have been described in the Korean literature. (4, 5) To the best of our knowledge, breast parenchymal myoid hamartoma with synchronous contralateral breast cancer has not been described. Our case manifested as a huge right breast myoid hamartoma with contralateral left invasive ductal carcinoma, which is unique.
Herein, we report the first case of myoid hamartoma of the breast parenchyma with synchronous contralateral breast cancer, and we review the relevant literatures.
CASE REPORT
A 46-yr-old woman visited our hospital due to masses in both breasts. She complained of a non-tender huge mass that had been slowly growing in her right breast for more than 3 yr, and she recently noticed a small left breast mass. Physical examination revealed a huge, firm, well circumscribed, painless mass that occupied the whole right breast and a hard, fixed, 2×2 cm mass in the periareolar area of the left breast. There were no skin changes of the breast or nipple retraction and no axillary lymphadenopathy was noted. Skin lesions, such as facial papules, trichilemmomas, oral papules, and palmoplantar keratosis were not present externally.
The patient had no other significant medical history and no family history of breast cancer. She had never undergone a breast examination, such as mammography or ultrasonography. An ultrasound examination showed a huge well-defined, heterogeneous echoic mass in the right breast and a 2×1.4 cm ill-defined, lobular hypoechoic mass in the periareolar area of the left breast. We performed ultrasound-guided core needle biopsy for both breast masses. Results revealed a stromal proliferative lesion of the right breast and an invasive ductal carcinoma of the left breast. A breast MRI showed a 9.2×7.2×7.1
Myoid hamartomas of the breast parenchyma are extremely rare, benign breast neoplasms. Only 15 cases of the parenchymal myoid hamartoma of the breast have currently been described in the medical literature written in English. A 46year-old woman presented with a huge right breast myoid hamartoma and synchronous contralateral left periareolar cancer. We discuss the clinical features, the radiologic find- Figure 2B ). Nuclear pleomorphism and mitoses were not present. Immunohistochemically, the stromal spindle cells were strongly positive for smooth muscle actin but they did not express CD34, the S-100 protein, or cytokeratin ( Figure 2C ). Ductal epithelial cells and stromal spindle cells showed nuclear positivity for the estrogen receptor, progesterone receptor, and phosphatase and tensin homolog deleted on chromosome ten (PTEN) ( Figure 2D ).
These microscopic and immunohistochemical findings indicated that the spindle cells in the stroma were smooth muscle cells. The ductal epithelial cells and stromal spindle cells showed nuclear positivity for the estrogen and progesterone receptors, and PTEN. We did not perform PTEN mutation study. Invasive ductal carcinoma was identified in the contralateral breast.
These histopathologic and immunohistochemical findings indicated that the case was a myoid hamartoma of the right breast parenchyma with a synchronous invasive ductal carcinoma of the left breast.
After operation, the patient was discharged without significant complications. Two years after surgery, the patient is doing well without recurrence or metastasis. To the best of our knowledge, this is the first case of myoid hamartoma of the breast parenchyma with syn-chronous contralateral breast cancer. The treatment of choice for breast hamartoma is surgical excision with tumor clear margins. If appropriate surgery is performed, the prognostic outcome is good.
DISCUSSION
In summary, myoid hamartoma of the breast parenchyma is extremely rare and frequently goes unrecognized by clinicians and pathologists because this lesion looks like other benign lesions. Awareness of myoid hamartoma of the breast parenchyma will be helpful to differentiate this benign tumor from other benign and physiologic changes in the breast.
